The Expert Angle

Medlior is a well-known and trusted industry leader.

Our team is dedicated to delivering high-quality research that provides a solid basis for informed decision-making.

Medlior’s Expert Angle offers the inside track on new studies, industry hot topics, and what you need to know in the fast-paced world of clinical research, all from the point of view of the Medlior team of experts. From the latest topics and trends to the foundations of health and medical research, Medlior explores topics relevant to clients and the world.

Report on virus-neutralizing monoclonal antibodies for the treatment of SARS-CoV-2

Report on virus-neutralizing monoclonal antibodies for the treatment of SARS-CoV-2

Medlior was pleased to work with the Canadian Agency for Drugs and Technologies in Health (CADTH) to prepare a report on virus-neutralizing monoclonal antibodies for the treatment of SARS-CoV-2 infection, as part of CADTH’s Coronavirus Disease (COVID-19) evidence bundle. The Medlior team ...
Looking Forward for 2021

Looking Forward for 2021

In January of 2020, we started the year with a passion for innovation and collaboration to produce impactful health outcomes research projects. We certainly could not have predicted the year that would follow, and while it was unprecedented, it also emphasized the vital role of health research ...
Looking back on 2020 – a year no one predicted

Looking back on 2020 – a year no one predicted

There’s not much that can be said about 2020 that hasn’t already been said. Unpredictable, unprecedented, unparalleled, 2020 will be remembered for a lot of things. But as we look towards 2021, we’re seeing hope like we haven’t seen in many months. With vaccines getting approved from ...
Calgary business owner, Tara Cowling, named Top 100 Female Entrepreneurs in Canada

Calgary business owner, Tara Cowling, named Top 100 Female Entrepreneurs in Canada

The top 100 Canadian businesses are presented by Scotiabank Women Initiative, the National Post, and Visa Canada Calgary, AB (December 1, 2020) - Calgary business owner and founder of Medlior Health Research Outcomes Ltd, Tara Cowling, has been named as one of the Top 100 female entrepreneurs ...
Indirect analysis of first-line therapy for advanced non-small cell lung cancer with activating mutations in the Japanese population

Indirect analysis of first-line therapy for advanced non-small cell lung cancer with activating mutations in the Japanese population

Medlior presents the recent publication, “Indirect analysis of first-line therapy for advanced non-small cell lung cancer with activating mutations in the Japanese population,” on first-line treatments of epidermal growth factor receptor mutation positive (EGFR+) non small cell lung cancer ...
Network meta-analysis of first-line therapy for advanced Epidermal Growth Factor Receptor mutation positive non-small cell lung cancer

Network meta-analysis of first-line therapy for advanced Epidermal Growth Factor Receptor mutation positive non-small cell lung cancer

Updated overall survival on the first-line treatments for advanced epidermal growth factor receptor mutation positive non-small cell lung cancer Lung cancer is the leading cause of death in Canada, with approximately 29,300 Canadians developing lung cancer in 2019.1 There are two forms of ...
EBMT 2020: Work and Productivity Loss in Patients with Acute Leukemia

EBMT 2020: Work and Productivity Loss in Patients with Acute Leukemia

The Impact of Hematopoietic Stem Cell Transplantation on Work and Productivity Loss in Patients with Acute Leukemia – Results from a Rapid Review This year, the 46th annual meeting for the European Group for Blood and Marrow Transplant (EBMT) has gone virtual! Medlior presented its evidence ...
EHDEN & HDRN Canada – streamlining access to COVID-19 data to facilitate insights and care

EHDEN & HDRN Canada – streamlining access to COVID-19 data to facilitate insights and care

Due to the global pandemic of COVID-19, we find ourselves in a time of unprecedented focus on health research. The call to action is clear: discover novel treatments, improve care practices, and ultimately cure COVID-19. The need to collaborate quickly and effectively across and within the ...
The Health Research Ethics Board of Alberta – Community Health Committee: a valuable partner for research success

The Health Research Ethics Board of Alberta – Community Health Committee: a valuable partner for research success

The Health Research Ethics Board of Alberta - Community Health Committee (HREBA-CHC) provides tremendous value for community-based research organizations in Alberta. Over the past four years, Medlior’s Calgary-based research team has conducted ten industry-sponsored Real World Evidence ...
Case Study: Atherosclerotic Cardiovascular Disease

Case Study: Atherosclerotic Cardiovascular Disease

Medlior’s RWE study examining the treatment landscape and clinical outcomes for patients with atherosclerotic cardiovascular disease in Alberta Introduction Medlior Health Outcomes Research Ltd. was engaged by Amgen Inc., one of the world’s leading biopharmaceutical companies, to examine ...
Network Meta-Analysis of First-line treatments for non-small cell lung cancer – ISPOR 2020

Network Meta-Analysis of First-line treatments for non-small cell lung cancer – ISPOR 2020

Medlior presented exciting new results from a network meta-analysis (NMA) project sponsored by Pfizer Inc., at the Virtual ISPOR 2020 Annual Meeting. This poster presentation compared the effects of first-line treatments for non-small cell lung (NSCLC). A brief overview of the presentation is ...
EAHAD 2020: Haemophilia-A SLR Project

EAHAD 2020: Haemophilia-A SLR Project

Haemophilia-A (HA) is a congenital x‐linked bleeding disorder caused by a deficiency of blood coagulation factor VIII (FVIII), occurring in approximately one in every 5000 male live births. HA is currently without a cure and therefore requires life-long monitoring and treatment of potentially life‐threatening bleeding events. Existing treatments for the management of this disorder include the use of plasma‐derived factor concentrates, recombinant factor concentrates, and more recently, monoclonal antibodies (e.g. emicizumab).